Elevated angiogenin levels in chronic heart failure

Figures & data

Table I.  Angiogenin levels and cardiovascular and metabolic characteristics of patients with chronic heart failure and control subjects

	Controls (n=109)		Chronic heart failure (n=112)		P
Age (years)	60.2	(10.1)	62.8	(12.7)	0.10
Body-mass index (kg/m^2)	26.7	(3.7)	27.9	(4.8)	0.05
Systolic BP (mmHg)	143	(19)	140	(24)	0.31
Diastolic BP (mmHg)	86.6	(9.3)	83.0	(14.1)	0.03
Heart rate (beats/min)	68.3	(12.8)	71.6	(13.6)	0.07
Fasting plasma glucose (mmol/L)	5.02	(0.47)	6.62	(3.64)	<0.001
Insulin (µ/mL)^a	7.3	(4.8, 11.0)	10.3	(6.5, 16.1)	<0.001
% Diuretic therapy	2.8	(3)	71.4	(80)	<0.001
% Beta-blocker therapy	4.6	(5)	63.4	(71)	<0.001
% ACE inhibitor therapy	7.3	(8)	90.2	(101)	<0.001
% Antithrombotic therapy	4.6	(5)	77.7	(87)	<0.001
% Lipid-lowering therapy	2.8	(3)	65.2	(73)	<0.001
Serum cholesterol (mmol/L)	5.19	(0.98)	4.42	(1.03)	<0.001
Serum triglycerides (mmol/L) ^a	1.10	(0.80, 1.50)	1.20	(0.93, 1.85)	<0.001
HDL cholesterol (mmol/L)	1.46	(0.36)	1.24	(0.35)	<0.001
Brain natriuretic peptide (pmol/L) ^a	4.7	(2.8,8.8)	41.8	(15.9, 82.9)	<0.001
LV ejection fraction	0.630	(0.082)	0.337	(0.103)	<0.001
Angiogenin (ng/mL) ^a	310	(264, 376)	466	(314, 739)	<0.001

Data are mean (SD),% (n).

^aData are median (IQR).

LV = left ventricular; ACE = angiotensin-converting enzyme; BP = Blood pressure; HDL = High Density Lipoprotein.

Table II.  Angiogenin levels in patients with chronic heart failure.

Angiogenin (ng/mL)	n	Median	Interquartile range
Gender
Female	25	420	321	708
Male	85	478	302	753
Ethnicity
White European	43	403	300	688
African Caribbean	21	485	350	813
South Asian	45	486	296	815
History of myocardial infarction
No	47	420	261	721
Yes	63	478	327	813
History of hypertension
No	56	407	298	722
Yes	54	517	329	759
History of diabetes
No	70	411	302	677
Yes	40	563	327	863
History of hyperlipidaemia
No	57	420	321	722
Yes	53	485	302	798
Previous smoking history
No	46	407	312	653
Yes	64	501	312	807
Regular alcohol intake
No	50	480	314	770
Yes	60	437	306	732
Diuretic therapy
No	31	380	259	789
Yes	79	479	333	736
ACE inhibitor therapy
No	11	454	380	736
Yes	99	469	311	749
Beta-blocker therapy
No	41	479	347	715
Yes	69	403	302	743
Spironolactone therapy
No	90	466	302	723
Yes	20	462	360	981
Antithrombotic therapy
No	21	454	266	909
Yes	85	469	327	743
Lipid-lowering therapy
No	38	437	323	832
Yes	72	479	305	734
NYHA classification
I	16	377	260	713
II	55	469	296	883
III	38	519	362	743

All comparisons, P = NS; NYHA = New York Heart Association; ACE = angiotensin-converting enzyme.

Figure 1.  Ordinal regression analysis of New York Heart Association (NYHA) classification and serum angiogenin.

Table III.  Correlation between levels of angiogenin and cardiac risk markers in patients and controls.

Association with levels of plasma angiogenin (ng/mL)	Spearman's correlation coefficient	Sig. (two-tailed)
Age (years)	0.183	0.005
Body-mass index (kg/m^2)	0.054	0.414
Systolic BP (mmHg)	−0.035	0.597
Diastolic BP (mmHg)	−0.135	0.038
Heart rate (beats/min)	0.024	0.712
Fasting plasma glucose (mmol/L)	0.244	<0.001
Insulin (µ/mL)	0.242	<0.001
Insulin resistance (HOMA IR)	−0.151	0.034
Serum cholesterol (mmol/L)	−0.106	0.105
Serum triglycerides (mmol/L)	0.095	0.145
HDL cholesterol (mmol/L)	−0.043	0.506
Brain natriuretic peptide (pmol/L)	0.305	<0.001
Simpson's LV ejection fraction	−0.283	0.002

BP = Blood pressure; HDL = High Density Lipoprotein; HOMA = homeostasis model assessment; IR = Insulin Resistance; LV = Left Ventricular.